Manufacturers seeking to gain reimbursement for blood thinners designed to replace oral warfarin as the drug-of-choice for preventing atrial fibrillation-associated stroke are facing tough battles in the U.K. from both the cost-watchdog, the National Institute for Health and Clinical Excellence (NICE), and from regional payers.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?